참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 3-Aminopyridine | HCID 10009 | — |
| 반응물 | 2,4-Dichloropyridine | HCID 33515 | — |
| 시약 | Cesium carbonate | HCID 10796 | — |
| 촉매 | 1,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine) | HCID 636044 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 용매 | 1,4-Dioxane | HCID 31275 | — |
| 생성물 | 4-chloro-N-pyridin-3-ylpyridin-2-amine | HCID 102218512 | 51.48% |
반응 단계
pyridin-3-amine (95 mg, 1.01 mmol), 2,4-dichloropyridine (0.151 mL, 1.01 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (70.4 mg, 0.12 mmol) and cesium carbonate (660 mg, 2.03 mmol) were stirred in dioxane (5 mL). The mixture was purged with nitrogen for 10 minutes. Palladium(II) acetate (22.76 mg, 0.10 mmol) was added and the mixture heated at 100 °C for 2h. The mixture was cooled, filtered and concentrated. The crude product was purified by flash silica chromatography, eluting gradient 5-45% EtOAc in isohexane. Fractions were evaporated to dryness and purified by flash silica chromatography, eluting at 35% EtOAc in isohexane to afford 4-chloro-N-(pyridin-3-yl)pyridin-2-amine (107 mg, 51.5 %) as a cream powder.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-3c36e457f5e64b5b9130db89ea6a541e |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|
